GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Short-Term Debt

Zydus Lifesciences (BOM:532321) Short-Term Debt : ₹0 Mil (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Short-Term Debt?

Zydus Lifesciences's Short-Term Debt for the quarter that ended in Dec. 2024 was ₹0 Mil.

Zydus Lifesciences's quarterly Short-Term Debt increased from Jun. 2024 (₹0 Mil) to Sep. 2024 (₹1,500 Mil) but then declined from Sep. 2024 (₹1,500 Mil) to Dec. 2024 (₹0 Mil).

Zydus Lifesciences's annual Short-Term Debt declined from Mar. 2022 (₹38,339 Mil) to Mar. 2023 (₹11,632 Mil) and declined from Mar. 2023 (₹11,632 Mil) to Mar. 2024 (₹7,686 Mil).

Zydus Lifesciences Short-Term Debt Historical Data

The historical data trend for Zydus Lifesciences's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Short-Term Debt Chart

Zydus Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47,718.00 39,740.00 38,339.00 11,632.00 7,686.00

Zydus Lifesciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 7,686.00 - 1,500.00 -

Zydus Lifesciences Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Zydus Lifesciences Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zydus Lifesciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Short-Term Debt
Comparable Companies
BOM:500257 BOM:500124 NSE:AUROPHARMA BOM:543904 NSE:TORNTPHARM BOM:500488 NSE:ALKEM BOM:500087 BOM:532296 BOM:524494 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
ZYDUSLIFE:India
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Website
https://www.zyduslife.com
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are; Pharmaceuticals which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States followed by India, and other countries.

Zydus Lifesciences Headlines

No Headlines